Live feed08:30:00·12mPRReleasevia QuantisnowCelcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast CancerByQuantisnow·Wall Street's wire, on your screen.CELC· Celcuity Inc.Health Care
